News

Major success for T-DM1
Enlarge image

Clinical TrialsSwitzerlandAustria

Major success for T-DM1

02.10.2012 - Roche's trastuzumab emtansine (T-DM1) appears to keep its promises. The armed antibody significantly extended overall survival in breast cancer patients.

Roche presented the latest big pack of Phase III data for T-DM1 at the ESMO conference currently being held in Vienna. The EMILIA study has shown that people with previously treated HER2-positive metastatic breast cancer survived significantly longer when treated with T-DM1 compared to those who received the standard-of-care, a combination of lapatinib and capecitabine. Results showed the risk of death was reduced by 32% for people who received the antibody-drug conjugate compared to those who received lapatinib plus Xeloda (HR=0.68; P=0.0006). People in the study treated with trastuzumab emtansine survived a median of 5.8 months longer than those who received lapatinib and Xeloda  (median overall survival: 30.9 months vs. 25.1 months). No new safety signals were observed and adverse events (AEs) were consistent with those seen in previous studies, with fewer people who received trastuzumab emtansine experiencing Grade 3 or higher (severe) adverse events than those who received lapatinib plus Xeloda (40.8 percent vs. 57.0 percent).

Representatives from Roche and industry experts were "extremely pleased" with the results. "Roche is moving away from Herceptin, with successors that are not just an inch better, but much, much better," said Andrew Weiss from Vontobel. Simos Simeonidis from SG Cowen has laid out a bullish marketing scenario, expecting that T-DM1 could earn more than its predecessor Herceptin (US$5.4bn) last year. "And since it will probably be priced at a meaningful premium to Herceptin, we think T-DM1 could end up as one of the biggest biotech drugs", Simeonidis said.

Genentech Inc., a Roche subsidiary situated in San Francisco (USA), is the developer of T-DM1. The company has already filed a marketing application for the drug to the Food and Drug Administration (FDA) in the US. The development was accomplished under an agreement with ImmunoGen, Inc. from Waltham (USA). The company from Massachusetts provides the linker chemistry and the compound drug's cancer killing agent, which is targeted by the antibody (trastuzumab) to Her2neu tumour cell receptors. ImmunoGen calls its technology TAP, Targeted Antibody Payload. The cytotoxic agent is a derivative of maytansine that inhibits the assembly of microtubules. Maytansines are potent toxins that naturally occur in the shrubs and trees of the Genus Maytenus spp.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/major-success-for-t-dm1.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.95 EUR2.33%
  • 4SC0.92 EUR2.22%
  • BIOTEST80.77 EUR1.62%

FLOP

  • CYTOS0.27 CHF-6.90%
  • CO.DON2.56 EUR-3.40%
  • WILEX2.10 EUR-2.78%

TOP

  • CYTOS0.27 CHF58.8%
  • EPIGENOMICS5.20 EUR36.8%
  • FORMYCON10.74 EUR36.1%

FLOP

  • 4SC0.92 EUR-13.2%
  • CO.DON2.56 EUR-12.6%
  • BIOFRONTERA2.59 EUR-9.4%

TOP

  • SANTHERA92.00 CHF2321.1%
  • CO.DON2.56 EUR156.0%
  • BB BIOTECH185.30 EUR63.0%

FLOP

  • CYTOS0.27 CHF-91.9%
  • 4SC0.92 EUR-48.3%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 26.11.2014